Tokio Marine Asset Management Co. Ltd. Acquires 113 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tokio Marine Asset Management Co. Ltd. lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,302 shares of the company’s stock after acquiring an additional 113 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $496,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter worth $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $30,000. New Covenant Trust Company N.A. acquired a new stake in Neurocrine Biosciences during the first quarter worth about $32,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the second quarter valued at about $35,000. Finally, Plato Investment Management Ltd acquired a new position in Neurocrine Biosciences in the 1st quarter valued at approximately $41,000. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 4.4 %

NBIX stock opened at $117.44 on Friday. The business has a fifty day moving average of $118.50 and a 200-day moving average of $132.66. The company has a market cap of $11.89 billion, a P/E ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $107.84 and a twelve month high of $157.98.

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Royal Bank of Canada lowered their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. JPMorgan Chase & Co. raised their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Citigroup upped their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Finally, Jefferies Financial Group raised their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.